Ironwood Investment Management LLC Boosts Stake in Quanterix Corporation $QTRX

Ironwood Investment Management LLC lifted its position in Quanterix Corporation (NASDAQ:QTRX) by 811.3% in the 3rd quarter, Holdings Channel reports. The fund owned 194,074 shares of the company’s stock after acquiring an additional 172,777 shares during the quarter. Ironwood Investment Management LLC’s holdings in Quanterix were worth $1,054,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in the company. Ameriprise Financial Inc. lifted its stake in shares of Quanterix by 14.0% in the 2nd quarter. Ameriprise Financial Inc. now owns 4,236,877 shares of the company’s stock valued at $28,175,000 after purchasing an additional 521,639 shares during the period. Vanguard Group Inc. grew its stake in Quanterix by 4.7% in the third quarter. Vanguard Group Inc. now owns 2,647,515 shares of the company’s stock worth $14,376,000 after purchasing an additional 118,565 shares during the period. William Blair Investment Management LLC raised its holdings in Quanterix by 16.6% in the third quarter. William Blair Investment Management LLC now owns 1,315,280 shares of the company’s stock worth $7,142,000 after purchasing an additional 187,299 shares in the last quarter. Blue Water Life Science Advisors LP lifted its position in Quanterix by 157.3% during the second quarter. Blue Water Life Science Advisors LP now owns 957,747 shares of the company’s stock valued at $6,369,000 after buying an additional 585,572 shares during the period. Finally, Geode Capital Management LLC lifted its position in Quanterix by 2.4% during the second quarter. Geode Capital Management LLC now owns 887,080 shares of the company’s stock valued at $5,900,000 after buying an additional 21,210 shares during the period. Hedge funds and other institutional investors own 86.48% of the company’s stock.

Analyst Ratings Changes

A number of analysts have recently weighed in on QTRX shares. Wall Street Zen raised shares of Quanterix from a “sell” rating to a “hold” rating in a research report on Monday, December 29th. Weiss Ratings reissued a “sell (d-)” rating on shares of Quanterix in a research note on Thursday, January 22nd. Finally, Canaccord Genuity Group raised their target price on shares of Quanterix from $5.00 to $8.00 and gave the company a “hold” rating in a research note on Monday, December 22nd. One research analyst has rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $11.33.

Quanterix Price Performance

Shares of Quanterix stock opened at $4.76 on Friday. Quanterix Corporation has a 1-year low of $4.05 and a 1-year high of $8.77. The company’s fifty day simple moving average is $6.31 and its 200-day simple moving average is $6.01. The stock has a market capitalization of $223.43 million, a PE ratio of -1.89 and a beta of 1.05.

Quanterix (NASDAQ:QTRX) last announced its earnings results on Monday, March 2nd. The company reported ($0.38) EPS for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.11). The company had revenue of $41.40 million during the quarter, compared to the consensus estimate of $37.95 million. Quanterix had a negative return on equity of 23.96% and a negative net margin of 77.14%. As a group, research analysts anticipate that Quanterix Corporation will post -0.98 EPS for the current year.

About Quanterix

Quanterix Corporation is a life sciences and diagnostics company specializing in ultra-sensitive digital immunoassay platforms. Its proprietary Single Molecule Array (Simoa) technology enables researchers to detect and quantify proteins, peptides and nucleic acids at femtomolar concentrations, offering sensitivity that surpasses traditional immunoassay methods. By translating single-molecule detection into routine laboratory workflows, Quanterix aims to accelerate biomarker discovery and the development of novel diagnostics and therapeutics.

The company’s core product portfolio includes the Simoa HD-1 and HD-X Analyzers, which automate high-throughput digital immunoassays for quantifying low-abundance biomarkers.